SHERRY L. MESMAN APPOINTED AS CHIEF FINANCIAL OFFICER
OF MOLECULAR BIOSYSTEMS
SAN DIEGO, Aug. 3 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) (MBI) announced today that Sherry L. Mesman has been appointed vice president, finance and chief financial officer, effective Aug. 1, 1992. In this position, Mesman will have full responsibility for the corporate finance, accounting, treasury and investor relations functions of the company.
Most recently, Mesman, a CPA, has served as chief accounting officer and treasurer at MBI. Mesman joined the company in 1989 as director of accounting and MIS from the public accounting firm, Arthur Andersen & Co.
Vincent A. Frank, MBI's president and chief operating officer, commented: "We are very pleased to announce the promotion of Sherry Mesman to vice president, finance and chief financial officer. She has been a valuable member of our senior management team. With her broad background in accounting and finance, we expect she will play a major role in the achievement of our strategic goals."
Molecular Biosystems Inc., based in San Diego, is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound, magnetic resonance imaging and computerized tomography. Its flagship product, Albunex(R)-I.V., is currently awaiting final FDA approval.
-0- 8/3/92
/CONTACT: Beth Field Wallace of Molecular Biosystems, 619-452-0681 ext. 2212/
(MB) CO: Molecular Biosystems Inc. ST: California IN: MTC SU: PER

JB-JL -- SD004 -- 6206 08/03/92 13:28 EDT

COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.